Table A1.

Pretransplantation Variables for the Bortezomib-MMUD and Sirolimus-MUD Cohorts

Variable	Bortezomib-MMUD(n = 45)		Sirolimus-MUD(n = 176)		P
	No.	%	No.	%
Patient age, years					.45
Median	59		60
Range	26-72		20-74
Donor age, years					.17
Median	35		32
Range	20-65		19-56
Female sex	21	47	69	39	.40
Patient-donor sex match
F-F	13	29	26	15	.19
F-M	8	18	43	24
M-F	7	16	28	16
M-M	17	38	79	45
Diagnosis
AML	14	31	46	26	—
NHL	11	24	28	16
CLL/SLL/PLL	8	18	18	10
HL	4	9	12	7
MDS	4	9	28	16
ALL	2	4	8	5
MPD	2	4	13	7
MM	0	0	14	8
CML	0	0	4	2
Anemia/red cell disorder	0	0	4	2
Other*	0	0	1	1
Myeloid disease†	20	44	91	52	.41
High-risk disease‡	30	67	141	80	.07
Patient or donor CMV positive	31	69	118	67	.86
Prior transplantation	8	18	50	28	.15

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; F, female; HL, Hodgkin's lymphoma; M, male; MDS, myelodysplastic syndromes; MM, multiple myeloma; MPD, myeloproliferative disease; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; NHL, non-Hodgkin's lymphoma; PLL, prolymphocytic leukemia; SLL, small lymphocytic lymphoma.

^*Hemophagocytic lymphohistiocytosis.

^†AML, MDS, MPD, and CML.

^‡Patients other than those with AML or ALL in first complete response, CML in chronic phase, aplastic anemia, or MDS with refractory anemia, or refractory anemia with ringed sideroblasts.